KLK3 and prostate carcinoma: Regarding prostate cancer, a net molecular signature suggests a prevalence of glycosylation enzymes with a missense variant rs61752561 resulting in prostate specific antigen (PSA) extra glycosylation as well as other somatic variants causing the potential loss of glycosylation [142].